Gosselies, Belgium, May 05, 2026 (GLOBE NEWSWIRE) —
Gosselies, Belgium, May 5, 2026 – Neuvasq Biotechnologies (“Neuvasq”), a biotechnology company dedicated to advancing first-in-class disease modifying multispecific antibodies designed to repair neurovascular barriers in patients with ophthalmologic diseases, announced the presentation of new preclinical data demonstrating the therapeutic potential of targeting the Wnt co-receptors Gpr124 and Lrp6. This approach supports the maintenance and repair of the blood-retina barrier (BRB) with the potential to slow, halt, prevent or even reverse vision loss in retinal vascular diseases, such as Diabetic Macular Edema (DME) and wet Age-related Macular Degeneration (wAMD). The oral presentation entitled, “Novel multispecific Gpr124-targeting antibodies correct vascular pathology in preclinical retinopathy models”, was delivered on May 5th, 2026 at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting in Denver, Colorado.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
